Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aveanna Healthcare Holdings (AVAH) Cash & Equivalents (2021 - 2025)

Historic Cash & Equivalents for Aveanna Healthcare Holdings (AVAH) over the last 5 years, with Q3 2025 value amounting to $145.9 million.

  • Aveanna Healthcare Holdings' Cash & Equivalents rose 8590.66% to $145.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $145.9 million, marking a year-over-year increase of 8590.66%. This contributed to the annual value of $84.3 million for FY2024, which is 9181.65% up from last year.
  • As of Q3 2025, Aveanna Healthcare Holdings' Cash & Equivalents stood at $145.9 million, which was up 8590.66% from $100.7 million recorded in Q2 2025.
  • Aveanna Healthcare Holdings' 5-year Cash & Equivalents high stood at $145.9 million for Q3 2025, and its period low was $17.4 million during Q2 2022.
  • For the 5-year period, Aveanna Healthcare Holdings' Cash & Equivalents averaged around $65.3 million, with its median value being $56.0 million (2022).
  • In the last 5 years, Aveanna Healthcare Holdings' Cash & Equivalents plummeted by 8361.04% in 2022 and then surged by 12866.21% in 2023.
  • Quarter analysis of 5 years shows Aveanna Healthcare Holdings' Cash & Equivalents stood at $121.7 million in 2021, then plummeted by 84.21% to $19.2 million in 2022, then skyrocketed by 128.66% to $43.9 million in 2023, then soared by 91.82% to $84.3 million in 2024, then soared by 73.06% to $145.9 million in 2025.
  • Its Cash & Equivalents stands at $145.9 million for Q3 2025, versus $100.7 million for Q2 2025 and $71.5 million for Q1 2025.